Use this URL to cite or link to this record in EThOS: http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.642023
Title: Improving the efficiency of aminolevulinate-photodynamic therapy of skin cells by combining UVA irradiation and potent iron chelating agents
Author: Radka, T.
Awarding Body: University of Bath
Current Institution: University of Bath
Date of Award: 2013
Availability of Full Text:
Access from EThOS:
Access from Institution:
Abstract:
Photodynamic therapy (PDT) is widely used for the treatment of skin cancer. Mechanistically, in delta-aminolevulinic acid (ALA)-mediated PDT, the addition of ALA to cells bypasses the negative feedback control of heme biosynthesis, leading to accumulation of photosensitizing concentrations of protoporphyrin IX (PPIX). Subsequent activation of cellular PPIX with an external light source (usually red light, 550-750 nm) leads to generation of reactive oxygen species (ROS), resulting in cell death. The major side effect of ALA-PDT treatment is the pain experienced by patients. Management of treatment-related pain still remains a considerable challenge in patients. Further optimization of the treatment protocol including light source, dose and duration therefore seems crucial to try and address this issue. To improve the efficiency of ALA-PDT of skin cells in the present study three approaches were used: (i) The conventional light source was changed to UVA (320-400 nm) that is absorbed more efficiently by PPIX and is 40-fold more potent in killing cultured skin cells than red light; (ii) ALA treatment was combined with the potent iron chelators, salicylaldehyde isonicotinoyl hydrazone (SIH), pyridoxal isonicotinoyl hydrazone (PIH) or desferrioxamine (DFO) to further increase the accumulation of PPIX through the depletion of iron available for ferrochelatase-mediated bioconversion of PPIX to heme; (iii) ALA treatment was combined with UVA-activatable caged iron chelators (CICs) that do not chelate iron unless activated by UVA. The CICs used were aminocinnamoyl-based SIH derivatives, ‘BY123’ and ‘BY128’. Upon activation by UVA, these CICs release the active SIH allowing for specific localised release of iron chelator in the cells. Spontaneously immortalised HaCaT cell line and Met2 cancer line (squamous cell carcinoma) were used as cell models. Cells were pre-treated (or not) for 18 h with SIH, PIH or DFO (20-100 µM), then subjected to ALA (0.5 mM) for 2 h and irradiated with low doses of UVA (5-50 kJ/m2). The quantification of intracellular PPIX was carried out by both HPLC and spectrofluorimetry after treatments of cells with ALA alone or combined with chelators. Cell death was examined 24 h after UVA exposure of ALA+/-chelators-treated cells by flow cytometry using Annexin V-propidium iodide dual staining assay. Pretreatment of HaCaT cells with ALA caused a substantial increase in the intracellular levels of PPIX which in turn sensitized the cells to very low non-cytotoxic UVA doses. Pre-treatment with DFO, PIH and SIH followed by ALA treatment further enhanced the PPIX level in HaCaT cells and caused an additional level of photosensitization to low UVA doses. Among the chelators used, SIH combined with ALA provided the most efficient increase in PPIX and cell killing following UVA irradiation, even at a lower SIH concentration of 20 µM. Among the CICs used, both UVA-activated BY123 and BY128 were as effective as SIH in increasing the level of PPIX and cell killing in ALA-treated cells following exposure to low doses of UVA. UVA-based ALA-PDT combined with SIH (or its caged-derivatives BY123 and BY128) appears therefore to be a promising modality for topical PDT. The high lipophilicity of SIH (and its caged-derivatives) which facilitates skin penetration and their potent cytotoxicity at low UVA doses should therefore allow the current modality for topical PDT to be improved, through a reduction of the time of irradiation and therefore the duration of pain experienced during the treatment. The use of SIH-based CICs will be a safer alternative to topical ALA-PDT than ‘naked’ SIH, as application of these pro-chelators will substantially decrease the exposure of the surrounding normal skin tissue to strong iron chelators and their toxic side effects.
Supervisor: Not available Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID: uk.bl.ethos.642023  DOI: Not available
Share: